COVID-19 Therapeutics Authorized by FDA *At a Glance*

NON-HOSPITALIZED PATIENTS

		TESTING REQUIREMENTS	PRESCRIBING WINDOW	ELIGIBLE POPULATIONS
Monoclonal Antibody	**REGEN-COV*** (casirivimab plus imdevimab)	Positive direct SARS-CoV-2 viral test	Within 10 days after symptom onset	Adult and adolescent individuals (12 years of age and older who weigh at least 88 pounds [40 kg]) who are at high risk for severe COVID-19, including hospitalization or death. Please refer to FDA fact sheet for full list of Risks and Limitations: Regen-COV FDA
Monoclonal Antibody	**BAMLANIVIMAB PLUS ETESEVIMAB***	Positive direct SARS-CoV-2 viral test	Within 10 days after symptom onset	Adult and pediatric individuals, including neonates, at high risk for progressing to severe COVID-19, including hospitalization or death. Please refer to FDA fact sheet for full list of Risks and Limitations: Bamlanivimab plus Etesevimab FDA
Monoclonal Antibody	**SOTROVIMAB**	Positive direct SARS-CoV-2 viral test	Within 10 days after symptom onset	Adult and pediatric patients (at least 12 years of age and older weighing at least 88 pounds [40 kg]) at high risk for progressing to severe COVID-19, including hospitalization or death. Please refer to FDA fact sheet for full list of Risks and Limitations: Sotrovimab FDA
Monoclonal Antibody	**EVUSHELD** (tixagevimab co-packaged with cilgavimab)	Positive direct SARS-CoV-2 viral test	Pre-exposure	Adult and adolescent individuals (12 years of age and older who weigh at least 88 pounds [40 kg]) for pre-exposure prophylaxis for prevention of COVID-19. Please refer to FDA fact sheet for full list of Risks and Limitations: Evusheld FDA
Oral Antiviral	**PAXLOVID**	Positive direct SARS-CoV-2 viral test	Within 5 days of symptom onset	Adults and pediatric patients (12 years of age and older weighing at least 88 pounds [40 kg]) at high risk for progressing to severe COVID-19, including hospitalization or death. Please refer to FDA fact sheet for full list of Risks and Limitations: Paxlovid FDA
Oral Antiviral	**MOLNUPIRAVIR**	Positive direct SARS-CoV-2 viral test	Within 5 days of symptom onset	Adults at high risk for progressing to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate. Please refer to FDA fact sheet for full list of Risks and Limitations: Molnupiravir FDA

*Not expected to be effective against Omicron variant.